key: cord-0844033-6srt828m
authors: Fillâtre, Pierre; Dufour, Marie-José; Behillil, Sylvie; Vatan, Remi; Reusse, Pascale; Gabellec, Alice; Velmans, Nicolas; Montagne, Catherine; Du Coudret, Sophie Geffroy; Droumaguet, Edith; Merour, Véronique; Enouf, Vincent; Buzele, Rodolphe; Valence, Marion; Guillotel, Elena; Gagniere, Bertrand; Baidaliuk, Artem; Zhukova, Anna; Tourdjman, Mathieu; Thibault, Vincent; Grolhier, Claire; Pronier, Charlotte; Lescure, François-Xavier; Simon-Loriere, Etienne; Costagliola, Dominique; Van Der Werf, Sylvie; Tattevin, Pierre; Massart, Nicolas
title: A new SARS-CoV-2 variant poorly detected by RT-PCR on nasopharyngeal samples, with high lethality: an observational study
date: 2021-10-07
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.09.035
sha: 9c0e3b81ea67218b6b3c3537b5340eee6133cc87
doc_id: 844033
cord_uid: 6srt828m

OBJECTIVES: In early January 2021, an outbreak of nosocomial cases of COVID-19 emerged in Western France, with RT-PCR tests repeatedly negative on nasopharyngeal samples but positive on lower respiratory tract samples. Whole genome sequencing (WGS) revealed a new variant, currently defining a novel SARS-CoV-2 lineage: B.1.616. In March, WHO classified this variant as ‘under investigation’ (VUI). We analyzed the characteristics and outcomes of COVID-19 cases related to this new variant. METHODS: Clinical, virological, and radiological data were retrospectively collected from medical charts in the two hospitals involved. We enrolled inpatients with either: i) positive SARS-CoV-2 RT-PCR on a respiratory sample; ii) seroconversion with anti-SARS-CoV-2 IgG/IgM; iii) suggestive symptoms and typical features of COVID-19 on a chest CT scan. Cases were categorized as either: i) B.1.616; ii) variant of concern (VOC); iii) unknown. RESULTS: From January 1(st) to March 24(th), 2021, 114 patients fulfilled inclusion criteria: B.1.616 (n=39), VOC (n=32), and unknown (n=43). B.1.616-related cases were older than VOC-related cases (81 years interquartile range [IQR] [73-88], vs 73 years IQR [67-82], P<0.05) and their first RT-PCR tests were rarely positive (6/39, 15% vs 31/32, 97%, P<0.05). B.1.616 variant was independently associated with severe disease (multivariable Cox model HR 4.0 95% CI [1.5-10.9]), and increased lethality: 28-day mortality 18/39 (46%) for B.1.616, vs. 5/32 (16%) for VOC, P=0.006. CONCLUSION: We report a nosocomial outbreak of COVID-19 cases related to a new variant, B.1.616, poorly detected by RT-PCR on nasopharyngeal samples, with high lethality.

associated were the wife of a confirmed case who visited him just before he was diagnosed with COVID-19, and a physician who developed infection after taking care of a WGS-confirmed case.

Finally, among the 182 COVID-19 inpatients living outside of the B.1.616 epidemic area, 39 were screened for VOCs, of whom 28 (72%) were infected with the B.1.1.7 (n=27) or the B.1.351 (n=1) variants. These 28 patients, combined with the 4 patients from the B.1.616 epidemic area infected with a VOC, were assigned to the VOC group.

Baseline characteristics are displayed on Table 1 Table 2 ). In addition, the median cycle threshold (CT) in nasopharyngeal samples was higher in the B.1.616 and the unknown variant group, at 29 [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and 35 [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] , vs 19 [14] [15] [16] [17] [18] [19] [20] [21] [22] in the VOC group, P<0.001. Supplementary Fig 3 illustrate A clinical trial reported 39% of severe patients who required high-flow oxygen or more invasive support at day 28, as compared to 65% for B.1.616 cases in our study, but that study was conducted prior to the emergence of VOCs, patients enrolled were younger (mean, 60 years), and had less comorbidities (81% with ≥1 comorbidity) [16] . In-hospital mortality ranged from 21% to 36% in previous studies (21) , with higher mortality in nosocomial COVID-19 (22) , or in elderly patients [17] [18] [19] . The high mortality rate among B.1.616 cases in our study must be interpreted with caution, as patients enrolled combined both pejorative factors, age (median, 81 years [73-88]), and healthcare-acquisition (37/39, 95%). The B.1.616 group included both WGS-confirmed B.1.616 cases, and COVID-19 cases following close contact with a confirmed case (probable B.1.616), in the absence of WGS confirmation. This conservative bias implies that comparisons with controls may misjudge the actual differences, with the 25 probable cases being frails, therefore increasing morbidity. Other variants have been associated with an increase or a decrease in COVID-19 severity [4, 20] . By the time of this writing, four variants are classified by the WHO as VOC, based on 'evidence of an increase in transmissibility, more severe disease, significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures' [5] .

The second most salient feature of COVID-19 cases related to B.1.616 was the high number of negative or weakly positive RT-PCR tests on nasopharyngeal samples. Previous studies estimated that 10-16% of patients with COVID- 19 have negative RT-PCR tests on nasopharyngeal samples [21, 22] . A meta-analysis concluded that 1.8 to 33% of RT-PCR tests on first nasopharyngeal samples in COVID-19 patients are found negative [23] . In our study, 20/26 (77%) of B.1.616 cases with at least one positive RT-PCR were tested negative for RT-PCR on their first nasopharyngeal sample.

Failure to detect B.1.616-related COVID-19 with the gold-standard diagnostic test most likely contributed to the emergence of several clusters, since implementation of specific infection control measures mostly relied on virological confirmation during the study period. Retrospective review of medical charts found that, in several cases, the diagnosis was suspected early in the COVID-19 course, but specific infection control measures were interrupted once RT-PCR tests returned negative. Failure to detect B.1.616 on nasopharyngeal samples is even more problematic for the screening of contacts. Indeed, the incidence of nosocomial COVID-19 was much higher during the early phase of the outbreak, before we realized the low yield of nasopharyngeal samples for this variant. Of note, although 'diagnostic detection failures' is one of the criteria to define VOC, none of the four major VOCs nor any of the current VUI meet this classification J o u r n a l P r e -p r o o f criteria. As RT-PCR assays used in France target at least two different viral genomic regions, it is unlikely that the B.1.616 strain would not be detected due to specific mismatches. Identification of this new lineage in lower respiratory tract samples confirmed the correct detection of the viral genome by commercially available assays used during the study period. Repeated failures to detect B.1.616 on nasopharyngeal samples were therefore most likely due to SARS-CoV-2 viral loads below detection threshold in this site, rather than sub-optimal sensitivity of routine RT-PCR tests. Of note, RT-PCR was positive on nasopharyngeal samples for only 32% of patients with pneumonia due to SARS-CoV [24] , and the Middle East respiratory syndrome-related coronavirus (MERS-CoV) is mostly detected in lower respiratory tract specimens, with high viral load, whereas nasopharyngeal specimens are poorly contributive [25] .

In our study, among patients with a positive RT-PCR assay in the B.1.616 group, the sensitivity of one, two, three, and four tests on nasopharyngeal samples were, respectively, 6/39 (15%), 15/39 (38%), 16 Our study has limitations. First, the small sample size and the retrospective design both limit the statistical power.

However, due to the fast pace of the pandemic, early communication on the characteristics of new variants is warranted, and this would be the first case series of B.1.616-related COVID-19 cases. Second, B.1.616 confirmed cases where those for whom a deep respiratory sample was obtained, mostly motivated by disease severity, hence constituting a selection bias. Finally, the selection of controls may be an additional limitation: VOC-related cases were selected as controls mostly because these cases could be reliably classified as 'non-B.1.616'. Since VOC screening was not performed up until February 10th, misclassification may have occurred, with inclusion of VOC cases among the 25 probable B.1.616 cases. However, the proportion of VOC in this area was very low on January 7th, estimated at less than 1% [26] .

Moreover, inclusion of VOC patients in the B.1.616 group would lead to underestimation of differences between groups.

In addition, all consecutive cases with available VOC screening were enrolled in the control group, which limits selection bias.

We report a nosocomial outbreak of COVID- 19 Note. VOC, variant of concern, * Note. WHO, world health organization; VOC, variant of concern J o u r n a l P r e -p r o o f Note. VOC, variant of concern J o u r n a l P r e -p r o o f 

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature

Nouveau variant détecté et sous surveillance en Bretagne n

Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review

Incidence of Nosocomial COVID-19 in Patients Hospitalized at a Large US Academic Medical Center

WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

Evasion of Type I Interferon by SARS-CoV-2

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Nosocomial Transmission of Coronavirus Disease 2019: A Retrospective Study of 66 Hospital-acquired Cases in a London Teaching Hospital

Predictors of In-Hospital Mortality in Older Patients With COVID-19: The COVIDAge Study

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Dexamethasone in Hospitalized Patients with Covid-19

False-negative results of initial RT-PCR assays for COVID-19: A systematic review

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission

Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France